Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Harmony Biosciences鈥� filings means wading into pages of clinical trial tables, FDA correspondence, and royalty math. If tracking WAKIX revenue trends or matching orexin pipeline milestones to cash runway feels overwhelming, you鈥檙e not alone. Harmony Biosciences SEC filings explained simply is exactly what most investors search for鈥攁nd what Stock Titan delivers.
Our platform adds AI context to every document the moment it appears on EDGAR. The latest Harmony Biosciences quarterly earnings report 10-Q filing is paired with sentence-level summaries that highlight net product sales, R&D spend, and upcoming Phase 3 readouts. A 300-page Harmony Biosciences annual report 10-K simplified shows side panels with trend graphs, while each Harmony Biosciences 8-K material events explained note spells out why an FDA Fast Track designation or safety update matters. Need governance data? The Harmony Biosciences proxy statement executive compensation section links pay packages to regulatory milestones so you can judge incentive alignment in minutes.
Compliance watchers rely on our real-time alerts for Harmony Biosciences Form 4 insider transactions real-time; one click reveals Harmony Biosciences insider trading Form 4 transactions alongside historical charts. Questions like 鈥渦nderstanding Harmony Biosciences SEC documents with AI鈥� or 鈥淗armony Biosciences earnings report filing analysis鈥� are answered through concise dashboards that connect filings to market impact. You can even export the full log of Harmony Biosciences executive stock transactions Form 4 for pattern analysis. With comprehensive coverage, AI-powered summaries, and instant access to every form type, Stock Titan turns dense biotech disclosure into clear, actionable insight.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), sold 21,573 shares of the company's common stock on 08/15/2025 under a Rule 10b5-1 trading plan. The transactions were executed at a weighted average price of $36.4983 per share, with individual sale prices ranging from $36.11 to $36.87. After these dispositions, the Form 4 reports 0 shares beneficially owned by the reporting person. The filing notes the sale was made pursuant to an established trading plan and offers to provide, upon request, the number of shares sold at each price within the disclosed range.
Harmony Biosciences Holdings, Inc. (HRMY) filed a Form 144 reporting a proposed sale of 21,573 common shares, representing restricted stock units acquired on 03/29/2023. The sale is to be executed through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $787,630.23 and an indicated approximate sale date of 08/15/2025. The filing shows 57,532,601 shares outstanding and indicates no securities sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information and discloses the sale is related to previously granted RSUs.
FAQ
What is the current stock price of Harmony Biosciences Holdings (HRMY)?
What is the market cap of Harmony Biosciences Holdings (HRMY)?
